Skip to main content
Premium Trial:

Request an Annual Quote

GSK and ViroLogic Pen $7.5M Supply Deal for HIV Drug Development

NEW YORK, Feb. 3 (GenomeWeb News) - ViroLogic and GlaxoSmithKline have signed a 3-year, $7.5 million service agreement in which ViroLogic will provide its PhenoSense HIV co-receptor tropism assay for use in the drug giant's discovery and development efforts, the companies said today.

 

Glaxo will use PhenoSense in its entry-inhibitor drug program, and other virologic efforts, to identify patients for clinical trials and monitor drug treatment response during trials, the companies said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.